Development of an antivirulence drug against Streptococcus mutans: repression of biofilm formation, acid tolerance, and competence by a histidine kinase inhibitor, walkmycin C
about
Biologically inspired strategies for combating bacterial biofilmsSmall molecule control of bacterial biofilmsA biochemical characterization of the DNA binding activity of the response regulator VicR from Streptococcus mutansEscherichia coli resistance to nonbiocidal antibiofilm polysaccharides is rare and mediated by multiple mutations leading to surface physicochemical modificationsSmall-molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence.Inactivation of multiple bacterial histidine kinases by targeting the ATP-binding domain.Relevance of the two-component sensor protein CiaH to acid and oxidative stress responses in Streptococcus pyogenes.In vitro manganese-dependent cross-talk between Streptococcus mutans VicK and GcrR: implications for overlapping stress response pathwaysBacterial signal transduction networks via connectors and development of the inhibitors as alternative antibiotics.The two-component system VicRK regulates functions associated with Streptococcus mutans resistance to complement immunity.Inhibition of Streptococcus mutans biofilm formation, extracellular polysaccharide production, and virulence by an oxazole derivative.Relevance of spontaneous fabT mutations to a streptococcal toxic shock syndrome to non-streptococcal toxic shock syndrome transition in the novel-type Streptococcus pyogenes isolates that lost a salRK.Two-component system VicRK regulates functions associated with establishment of Streptococcus sanguinis in biofilmsIsolation and characterization of signermycin B, an antibiotic that targets the dimerization domain of histidine kinase WalKAll signals lost.Screening for inhibitors of mutacin synthesis in Streptococcus mutans using fluorescent reporter strains.
P2860
Q27006003-DCCB77B0-B5FB-438F-A415-D082D2DE9CDAQ28269575-DFA3F001-983D-4D28-AC48-AD86B5F31AC1Q28543046-766D2177-AEAF-4951-996A-BDF692A8DEC7Q30541729-92857340-994A-4FBC-8EFA-48435B461D7FQ34823364-87160FCB-AE49-4140-9773-CC5D517643E8Q34992446-1CCE1590-7FB4-4340-8FE5-85EF49F02DEFQ35132824-BA056EFC-C893-4DFB-9D8F-2269D15D0ADEQ35533270-6E320695-D65B-463D-B4A3-81C03C07A615Q39457826-3660D17B-7B96-4462-94CE-1CBF38BD43ECQ40262634-89816A32-E797-4ABC-92EC-9C5FCBC72912Q40364785-A8C32CAE-D610-4EAB-999D-517174A6F33AQ40798247-2121A9D8-A25B-49D6-A0F6-8E95647BED31Q41756717-4CE53B5B-4F12-4C62-992D-A34F91CEC859Q41811635-BC45DCE3-81E2-4AEB-9907-B251FD98EDB7Q42406980-4D61B3D6-BEA8-4911-B5A4-B845C1AFD183Q55042084-7F7F5627-086E-43AB-A615-25472413BE06
P2860
Development of an antivirulence drug against Streptococcus mutans: repression of biofilm formation, acid tolerance, and competence by a histidine kinase inhibitor, walkmycin C
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@en
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@nl
type
label
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@en
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@nl
prefLabel
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@en
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@nl
P2093
P2860
P356
P1476
Development of an antivirulenc ...... kinase inhibitor, walkmycin C
@en
P2093
Hiroko Matsunaga
Masayuki Igarashi
Norihiro Kubo
Ryutaro Utsumi
Yoko Eguchi
P2860
P304
P356
10.1128/AAC.01646-10
P407
P577
2011-01-31T00:00:00Z